BFRG's Business Model
BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.
| Sector & Industry | Healthcare / Medical - Healthcare Information Services |
| Website | https://www.bullfrogai.com |
| CEO (Chief Executive Officer) | Vininder Singh |
| Number of Employees | |
| IPO date | February 13, 2023 |
BFRG Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 325 Ellington Blvd. |
| City | Gaithersburg |
| State | MD |
| Phone | 240 658 6710 |
| Zip Code | 20878 |
| Other Identifiers | |
| CIK | 0001829247 |
| ISIN | US12021E1091 |
| CUSIP | |
| Open | 0.759 |
| Previous Close | 0.759 |
| Volume | 187.6 Thou. |
| Average Volume | 562.2 Thou. |
| Day’s Range | 0.7 – 0.774 |
| 52 Week Range | 0.645-4.84 |
| MA (50) | 0.9677 |
| MA (200) | 1.37571 |
| Market Cap | 7.04 Mil. |
| Shares Out. | 9.72 Mil. |
| Earnings Date | Nov 14, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
